Zhitong Financial App News, Changjiang Life Technology (00775.HK) announced that Sequencio Therapeutics Company Limited (“Shunpu Pharmaceutical Technology”), a wholly-owned subsidiary of the company, will present the latest research data on its leading cancer vaccine projects at the 2026 Annual Meeting of the Society for Cancer Immunotherapy (SITC) in Phoenix, Arizona, USA, respectively, the TROP2 circRNA-LNP vaccine and PD-L1/ PRAME dual antigen vaccine.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.